Basilea Pharmaceutica receives additional $13.3M from BARDA for novel oral antibiotic
What's the deal? Swiss pharma company Basilea Pharmaceutica has received an additional $13.3M from the US Biomedical Advanced Research and Development Authority (BARDA) to continue developing its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil. The drug targets complicated urinary tract infections (cUTIs), including kidney infections, caused by multidrug-resistant bacteria.
After this latest tranche, BARDA has committed a total of $25M to the programme. The contract could provide up to $133M in additional non-dilutive funding.
Why now? Antibiotic resistance is a growing global health crisis. Many common bacteria now produce enzymes that neutralise standard antibiotics, leaving doctors with fewer treatment options — especially oral ones. There are currently no approved oral beta-lactam combinations effective against several key classes of resistant bacteria.
Basilea's drug has already received Qualified Infectious Disease Product and Fast Track designations from the US Food and Drug Administration (FDA), signalling regulatory urgency around the unmet need.
What could go wrong? The drug is still investigational and not approved anywhere for commercial use. Clinical development of antibiotics is notoriously difficult: many promising candidates fail in late-stage trials, and even those that succeed often struggle commercially due to low pricing and limited use.
The BARDA contract's full $133M is contingent on continued progress — there's no guarantee the remaining funds will be released.
The signal: Basilea, classified as a late-growth-stage commercial biopharma company on Dealroom, is leaning heavily on non-dilutive government funding to advance a programme that private capital has largely declined to back — a pattern increasingly common across the antibiotic sector. With up to $133M in potential BARDA support on the table, the deal underscores how public agencies are effectively becoming the lead investors in next-generation antimicrobials where traditional venture and pharma economics have broken down.
Read more: MarketScreener
